Trial Profile
A Multi-Institutional Phase 2 Study of Nivolumab or Nivolumab in Combination With Ipilimumab in Refractory Metastatic Squamous Cell Carcinoma of the Anal Canal
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 08 Mar 2024
Price :
$35
*
At a glance
- Drugs Ipilimumab (Primary) ; Nivolumab (Primary)
- Indications Anal cancer; Squamous cell cancer
- Focus Therapeutic Use
- 17 Feb 2024 Planned End Date changed from 15 Feb 2024 to 15 Feb 2025.
- 17 Feb 2024 Planned primary completion date changed from 15 Feb 2024 to 15 Feb 2025.
- 20 Jan 2024 Results analyzing serial blood samples from this study for immune biomarker profiling , presented at the 2024 Gastrointestinal Cancers Symposium